Search jobs Canadian Pathology Quality Assurance Leverages Diaceutics’ DXRX Platform to Advance NTRK IHC Proficiency Testing Canadian Pathology Quality Assurance will utilize the DXRX platform’s global network to support global implementation of their pan-TRK program Partnership will enable CPQA to produce best-in-class Neurotrophic Tropomyosin Receptor Kinase IHC proficiency testing Laboratories can sign up to the DXRX marketplace and avail of the opportunity to work with a world renowned External Quality Assessment provider DXRX is the world’s first diagnostic network for precision medicine, enabling industry-wide collaboration to get every patient the treatment they deserve PARSIPPANY, New Jersey--(BUSINESS WIRE)--Diaceutics PLC, (AIM: DXRX), today announces a strategic partnership with Canadian Pathology Quality Assurance (CPQA) to advance the development of Neurotrophic Tropomyosin Receptor Kinase (NTRK) IHC proficiency testing globally.